83 related articles for article (PubMed ID: 22405568)
1. Pemetrexed as a possible cause of severe rhabdomyolysis in the treatment of lung cancer.
Huang MS; Tsai JR; Shen MC; Chou SH; Yang CJ
Lung Cancer; 2012 Jun; 76(3):491-2. PubMed ID: 22405568
[TBL] [Abstract][Full Text] [Related]
2. Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.
Prescrire Int; 2005 Dec; 14(80):212-4. PubMed ID: 16400741
[TBL] [Abstract][Full Text] [Related]
3. Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study.
Xu Y; Ma S; Ji Y; Sun X; Jiang H; Chen J; Du X; Zheng Y; Qiu G
Lung Cancer; 2011 Jun; 72(3):327-32. PubMed ID: 21056507
[TBL] [Abstract][Full Text] [Related]
4. Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: a prospective, multicenter trial.
Lee HY; Ahn MJ; Park YH; Ahn JS; Kim BS; Kim HK; Kim HT; Ryoo HM; Bae SH; Lee SS; Choi K; Hong DS; Lee KH; Kwon JH; Choi IS; Kim BS; Lee NS; Gong SJ; Park K
Lung Cancer; 2009 Dec; 66(3):338-43. PubMed ID: 19299031
[TBL] [Abstract][Full Text] [Related]
5. Pemetrexed-induced anaphylaxis.
Shah BK; Hewett Y
Acta Oncol; 2013 May; 52(4):881. PubMed ID: 23472834
[No Abstract] [Full Text] [Related]
6. Pemetrexed: new indication. Untreated non-small cell lung cancer: just another cytotoxic drug. No better than the gemcitabine-cisplatin combination with a different safety profile, as is the case for other cytotoxic drugs.
Prescrire Int; 2009 Jun; 18(101):114. PubMed ID: 19637425
[No Abstract] [Full Text] [Related]
7. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
[TBL] [Abstract][Full Text] [Related]
8. Pemetrexed-induced skin sclerosis.
Merklen-Djafri C; Imbert E; Courouge-Dorcier D; Schott R; Méraud JP; Muller C; Tebacher M; Springinsfeld G; Cribier B; Lipsker D
Clin Oncol (R Coll Radiol); 2012 Aug; 24(6):452-3. PubMed ID: 22397832
[No Abstract] [Full Text] [Related]
9. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent.
Adjei AA
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4276s-4280s. PubMed ID: 15217974
[TBL] [Abstract][Full Text] [Related]
10. Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer.
Okamoto I; Takeda K; Daga H; Miyazaki M; Yonesaka K; Kiyota H; Tsurutani J; Ueda S; Ichikawa Y; Takeda M; Sekiguchi R; Tominaga K; Enatsu S; Nambu Y; Nakagawa K
Lung Cancer; 2010 Nov; 70(2):168-73. PubMed ID: 20236726
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancer.
Cardenal F; Arnaiz MD; Morán T; Jové J; Nadal E; Porta R; Solé JM; Brao I; Palmero R; Fuentes R; Núñez I; Caveda E; Cassinello A
Lung Cancer; 2011 Oct; 74(1):69-74. PubMed ID: 21353323
[TBL] [Abstract][Full Text] [Related]
12. Pemetrexed safety and pharmacokinetics in patients with third-space fluid.
Dickgreber NJ; Sorensen JB; Paz-Ares LG; Schytte TK; Latz JE; Schneck KB; Yuan Z; Sanchez-Torres JM
Clin Cancer Res; 2010 May; 16(10):2872-80. PubMed ID: 20460481
[TBL] [Abstract][Full Text] [Related]
13. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer.
Clarke SJ; Boyer MJ; Millward M; Underhill C; Moylan E; Yip D; White S; Childs A; Beale P; Latz J; Suri A; Iglesias JL
Lung Cancer; 2005 Sep; 49(3):401-12. PubMed ID: 15923057
[TBL] [Abstract][Full Text] [Related]
14. Safety of systemic chemotherapy in a patient with mitochondrial myopathy and non-small-cell lung cancer.
Catania C; Spitaleri G; Delmonte A; Giovannini M; Toffalorio F; Noberasco C; Bresolin N; Comi G; De Pas T
J Clin Oncol; 2012 Aug; 30(24):e226-8. PubMed ID: 22711848
[No Abstract] [Full Text] [Related]
15. Carboplatin-pemetrexed adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC): a phase II study.
Karapanagiotou EM; Boura PG; Papamichalis G; Konstantinou M; Sepsas E; Chamalakis G; Simsiris P; Gkiozos I; Syrigos KN
Anticancer Res; 2009 Oct; 29(10):4297-301. PubMed ID: 19846990
[TBL] [Abstract][Full Text] [Related]
16. Pemetrexed in first-line treatment of non-small cell lung cancer.
Esteban E; Casillas M; Cassinello A
Cancer Treat Rev; 2009 Jun; 35(4):364-73. PubMed ID: 19269106
[TBL] [Abstract][Full Text] [Related]
17. Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer.
Bearz A; Garassino I; Tiseo M; Caffo O; Soto-Parra H; Boccalon M; Talamini R; Santoro A; Bartolotti M; Murgia V; Berretta M; Tirelli U
Lung Cancer; 2010 May; 68(2):264-8. PubMed ID: 19632738
[TBL] [Abstract][Full Text] [Related]
18. Pemetrexed-induced eyelid edema: incidence and clinical manifestations.
Schallier D; Decoster L; Fontaine C; De Grève J
Anticancer Res; 2010 Dec; 30(12):5185-8. PubMed ID: 21187510
[TBL] [Abstract][Full Text] [Related]
19. Toxic epidermal necrolysis after pemetrexed and cisplatin for non-small cell lung cancer in a patient with sharp syndrome.
Then C; von Einem JC; Müller D; Flaig MJ; Huber RM; Reincke M
Onkologie; 2012; 35(12):783-6. PubMed ID: 23207626
[TBL] [Abstract][Full Text] [Related]
20. Pemetrexed and cisplatin with concurrent radiotherapy for locally advanced non-small cell and limited disease small cell lung cancer: results from 2 phase I studies.
Surmont V; Smit EF; de Jonge M; Aerts JG; Nackaerts K; Vernhout R; Gras J; Van Wijk A; Phernambucq EC; van Meerbeeck JP; Senan S; Kraaij CJ; Chouaki N; Praag J; van Klaveren RJ
Lung Cancer; 2010 Sep; 69(3):302-6. PubMed ID: 20096951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
